For any item to be covered by Medicare, it must 1) be eligible for a defined
Medicare benefit category, 2) be reasonable and necessary for the diagnosis or
treatment of illness or injury or to improve the functioning of a malformed
body member, and 3) meet all other applicable Medicare statutory and
regulatory requirements.

The purpose of a Local Coverage Determination (LCD) is to provide information
regarding "reasonable and necessary" criteria based on Social Security Act 
1862(a)(1)(A) provisions.

In addition to the "reasonable and necessary" criteria contained in this LCD
there are other payment rules, which are discussed in the following documents,
that must also be met prior to Medicare reimbursement:

  * The LCD-related Standard Documentation Requirements Article, located at the bottom of this policy under the Related Local Coverage Documents section.

  * The LCD-related Policy Article, located at the bottom of this policy under the Related Local Coverage Documents section.

  * Refer to the Supplier Manual for additional information on documentation requirements.

  * Refer to the DME MAC web sites for additional bulletin articles and other publications related to this LCD.

For the items addressed in this LCD, the "reasonable and necessary" criteria,
based on Social Security Act  1862(a)(1)(A) provisions, are defined by the
following coverage indications, limitations and/or medical necessity.

DEFINITIONS

For purposes of this policy the following definitions are used:

\- FIO2 is the fractional concentration of oxygen delivered to the beneficiary
for inspiration. The beneficiary's prescribed FIO2 refers to the oxygen
concentration the beneficiary normally breathes when not undergoing testing to
qualify for coverage of a Respiratory Assist Device (RAD). That is, if the
beneficiary does not normally use supplemental oxygen, their prescribed FIO2
is that found in room air.

\- FEV1 is the forced expired volume in 1 second.

\- FVC is the forced vital capacity.

\- Central sleep apnea (CSA) is defined by all of the following:

  * An apnea-hypopnea index (AHI) greater than or equal to 5; and
  * The sum total of central apneas plus central hypopneas is greater than 50% of the total apneas and hypopneas; and
  * A central apnea-central hypopnea index (CAHI) is greater than or equal to 5 per hour; and
  * The presence of at least one of the following: 
    * Sleepiness
    * Difficulty initiating or maintaining sleep, frequent awakenings, or non-restorative sleep
    * Awakening short of breath
    * Snoring
    * Witnessed apneas
  * There is no evidence of daytime or nocturnal hypoventilation

  *  

\- Complex sleep apnea (CompSA) is a form of central apnea specifically
identified by all of the following:

  1. With use of a positive airway pressure device without a backup rate (E0601 or E0470), the polysomnogram (PSG) shows a pattern of apneas and hypopneas that demonstrates the persistence or emergence of central apneas or central hypopneas upon exposure to CPAP (E0601) or a bi-level device without backup rate (E0470) device when titrated to the point where obstructive events have been effectively treated (obstructive AHI less than 5 per hour).
  2. After resolution of the obstructive events, the sum total of central apneas plus central hypopneas is greater than 50% of the total apneas and hypopneas; and
  3. After resolution of the obstructive events, a central apnea-central hypopnea index (CAHI) greater than or equal to 5 per hour.

\- Apnea is defined as the cessation of airflow for at least 10 seconds.

\- Hypopnea is defined as an abnormal respiratory event lasting at least 10
seconds associated with at least a 30% reduction in thoracoabdominal movement
or airflow as compared to baseline, and with at least a 4% decrease in oxygen
saturation.

\- The apnea-hypopnea index (AHI) is defined as the average number of episodes
of apnea and hypopnea per hour of sleep without the use of a positive airway
pressure device.

\- For diagnosis of CSA, the central apnea-central hypopnea index (CAHI) is
defined as the average number of episodes of central apnea and central
hypopnea per hour of sleep without the use of a positive airway pressure
device. For CompSA, the CAHI is determined during the use of a positive airway
pressure device after obstructive events have disappeared.

\- If the AHI or CAHI is calculated based on less than 2 hours of continuous
recorded sleep, the total number of recorded events used to calculate the AHI
or CAHI must be at least the number of events that would have been required in
a 2-hour period (i.e., greater than or equal to 10 events).

\- See the Sleep Tests section below for a discussion of (PSG) and portable
home sleep testing (HST).

\- If there is discontinuation of usage of an E0470 or E0471 device at any
time, the supplier is expected to ascertain this, and stop billing for the
equipment and related accessories and supplies.

INITIAL COVERAGE CRITERIA FOR E0470 AND E0471 DEVICES FOR THE FIRST THREE
MONTHS OF THERAPY:

For an E0470 or an E0471 RAD to be covered, the treating practitioner must
fully document in the beneficiary's medical record symptoms characteristic of
sleep-associated hypoventilation, such as daytime hypersomnolence, excessive
fatigue, morning headache, cognitive dysfunction, dyspnea.

A RAD (E0470, E0471) is covered for those beneficiaries with one of the
following clinical disorders: restrictive thoracic disorders (i.e.,
neuromuscular diseases or severe thoracic cage abnormalities), severe chronic
obstructive pulmonary disease (COPD), CSA or CompSA, or hypoventilation
syndrome, as described in the following section.

Restrictive Thoracic Disorders

An E0470 or E0471 device is covered when criteria A - C are met.

  1. There is documentation in the beneficiary's medical record of a neuromuscular disease (for example, amyotrophic lateral sclerosis) or a severe thoracic cage abnormality (for example, post-thoracoplasty for TB).
  2. One of the following: 
    1. An arterial blood gas PaCO2, done while awake and breathing the beneficiary's prescribed FIO2 is greater than or equal to 45 mm Hg, or
    2. Sleep oximetry demonstrates oxygen saturation less than or equal to 88% for greater than or equal to 5 minutes of nocturnal recording time (minimum recording time of 2 hours), done while breathing the beneficiary's prescribed recommended FIO2, or
    3. For a neuromuscular disease (only), either i or ii, 
      1. Maximal inspiratory pressure is less than 60 cm H20, or
      2. Forced vital capacity is less than 50% predicted
  3. Chronic obstructive pulmonary disease does not contribute significantly to the beneficiary's pulmonary limitation.

If all of the above criteria are met, either an E0470 or an E0471 device
(based upon the judgment of the treating practitioner) will be covered for the
first three months of therapy.

If all of the above criteria are not met, then E0470 or E0471 and related
accessories will be denied as not reasonable and necessary.

See CONTINUED COVERAGE CRITERIA FOR E0470 AND E0471 DEVICES BEYOND THE FIRST
THREE MONTHS for information on more than three months use.

Severe COPD

An E0470 device is covered if criteria A - C are met.

  1. An arterial blood gas PaCO2, done while awake and breathing the beneficiary's prescribed FIO2, is greater than or equal to 52 mm Hg.
  2. Sleep oximetry demonstrates oxygen saturation less than or equal to 88% for greater than or equal to a cumulative 5 minutes of nocturnal recording time (minimum recording time of 2 hours), done while breathing oxygen at 2 LPM or the beneficiary's prescribed FIO2 (whichever is higher).
  3. Prior to initiating therapy, sleep apnea and treatment with a continuous positive airway pressure device (CPAP) has been considered and ruled out. (Note: Formal sleep testing is not required if there is sufficient information in the medical record to demonstrate that the beneficiary does not suffer from some form of sleep apnea (Obstructive Sleep Apnea (OSA), CSA and/or CompSA) as the predominant cause of awake hypercapnia or nocturnal arterial oxygen desaturation).

If all of the above criteria for beneficiaries with COPD are met, an E0470
device will be covered for the first three months of therapy.

If all of the above criteria are not met, E0470 and related accessories will
be denied as not reasonable and necessary.

An E0471 device will be covered for a beneficiary with COPD in either of the
two situations below, depending on the testing performed to demonstrate the
need.

_Situation 1._ For severe COPD beneficiaries who qualified for an E0470
device, an E0471 started any time after a period of initial use of an E0470
device is covered if both criteria A and B are met.

  1. An arterial blood gas PaCO2, done while awake and breathing the beneficiary's prescribed FIO2, shows that the beneficiary's PaCO2 worsens greater than or equal to 7 mm Hg compared to the original result from criterion A, (above).
  2. A facility-based PSG demonstrates oxygen saturation less than or equal to 88% for greater than or equal to a cumulative 5 minutes of nocturnal recording time (minimum recording time of 2 hours) while using an E0470 device that is not caused by obstructive upper airway events - i.e., AHI less than 5. (Refer to the Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea LCD for information about E0470 coverage for obstructive sleep apnea).

_Situation 2._ For severe COPD beneficiaries who qualified for an E0470
device, an E0471 device will be covered if, at a time no sooner than 61 days
after initial issue of the E0470 device, both of the following criteria A and
B are met:

  1. An arterial blood gas PaCO2 is done while awake and breathing the beneficiary's prescribed FIO2, still remains greater than or equal to 52 mm Hg.
  2. Sleep oximetry while breathing with the E0470 device, demonstrates oxygen saturation less than or equal to 88% for greater than or equal to a cumulative 5 minutes of nocturnal recording time (minimum recording time of 2 hours), done while breathing oxygen at 2 LPM or the beneficiary's prescribed FIO2 [whichever is higher].

If E0471 is billed but the criteria described in either situation 1 or 2 are
not met, it will be denied as not reasonable and necessary.

See CONTINUED COVERAGE CRITERIA FOR E0470 AND E0471 DEVICES BEYOND THE FIRST
THREE MONTHS for information on more than three months use.

Central Sleep Apnea or Complex Sleep Apnea

An E0470 or E0471 device is covered when, prior to initiating therapy, a
complete facility-based, attended PSG is performed documenting the following
(A and B):

  1. The diagnosis of CSA or CompSA; and
  2. Significant improvement of the sleep-associated hypoventilation with the use of an E0470 or E0471 device on the settings that will be prescribed for initial use at home, while breathing the beneficiary's prescribed FIO2.

If all of the above criteria are met, either an E0470 or an E0471 device
(based upon the judgment of the treating practitioner) will be covered for
beneficiaries with documented CSA or CompSA for the first three months of
therapy.

If all of the above criteria are not met, then E0470 or E0471 and related
accessories will be denied as not reasonable and necessary.

See CONTINUED COVERAGE CRITERIA FOR E0470 AND E0471 DEVICES BEYOND THE FIRST
THREE MONTHS for information on more than three months use.

Hypoventilation Syndrome

An E0470 device is covered if both criteria A and B and either criterion C or
D are met.

  1. An initial arterial blood gas PaCO2, done while awake and breathing the beneficiary's prescribed FIO2, is greater than or equal to 45 mm Hg
  2. Spirometry shows an FEV1/FVC greater than or equal to 70%. (Refer to SEVERE COPD (above) for information about device coverage for beneficiaries with FEV1/FVC less than 70%.)
  3. An arterial blood gas PaCO2, done during sleep or immediately upon awakening, and breathing the beneficiary's prescribed FIO2, shows the beneficiary's PaCO2 worsened greater than or equal to 7 mm Hg compared to the original result in criterion A (above).
  4. A facility-based PSG or HST demonstrates oxygen saturation less than or equal to 88% for greater than or equal to 5 minutes of nocturnal recording time (minimum recording time of 2 hours) that is not caused by obstructive upper airway events - i.e., AHI less than 5. (Refer to the Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea LCD for information about E0470 coverage for obstructive sleep apnea.)

If the above criteria are not met, E0470 and related accessories will be
denied as not reasonable and necessary.

An E0471 device is covered for a beneficiary with hypoventilation syndrome if
both criteria A, B, and either criterion C or D are met:

  1. A covered E0470 device is being used.
  2. Spirometry shows an FEV1/FVC greater than or equal to 70%. (Refer to SEVERE COPD (above) for information about device coverage for beneficiaries with FEV1/FVC less than 70%).
  3. An arterial blood gas PaCO2, done while awake, and breathing the beneficiary's prescribed FIO2, shows that the beneficiary's PaCO2 worsens greater than or equal to 7 mm Hg compared to the arterial blood gas (ABG) result performed to qualify the beneficiary for the E0470 device (criterion A under E0470).
  4. A facility-based PSG or HST demonstrates oxygen saturation less than or equal 88% for greater than or equal to 5 minutes of nocturnal recording time (minimum recording time of 2 hours) that is not caused by obstructive upper airway events - i.e., AHI less than 5 while using an E0470 device. (Refer to the Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea LCD for information about E0470 coverage for obstructive sleep apnea.)

If the criteria above are not met, an E0471 device will be denied as not
reasonable and necessary.

See CONTINUED COVERAGE CRITERIA FOR E0470 AND E0471 DEVICES BEYOND THE FIRST
THREE MONTHS for information on more than three months use.

VENTILATORS

The Centers for Medicare & Medicaid Services (CMS) National Coverage
Determinations Manual (CMS Pub. 100-03) in Chapter 1, Part 4, Section 280.1
stipulates that ventilators (E0465, E0466, and E0467) are covered for the
following conditions:

"[N]euromuscular diseases, thoracic restrictive diseases, and chronic
respiratory failure consequent to chronic obstructive pulmonary disease."

Each of these disease categories are comprised of conditions that can vary
from severe and life-threatening to less serious forms. These ventilator-
related disease groups overlap conditions described in this Respiratory Assist
Devices LCD used to determine coverage for bi-level PAP devices. Each of these
disease categories are conditions where the specific presentation of the
disease can vary from beneficiary to beneficiary. For conditions such as
these, the specific treatment plan for any individual beneficiary will vary as
well. Choice of an appropriate treatment plan, including the determination to
use a ventilator vs. a bi-level PAP device, is made based upon the specifics
of each individual beneficiary's medical condition. In the event of a claim
review, there must be sufficient detailed information in the medical record to
justify the treatment selected.

Ventilators fall under the Frequent and Substantial Servicing (FSS) payment
category, and payment policy requirements preclude FSS payment for devices
used to deliver continuous and/or intermittent positive airway pressure,
regardless of the illness treated by the device. (Social Security Act
1834(a)(3)(A)) This means that products currently classified as HCPCS code
E0465, E0466, or E0467 when used to provide CPAP or bi-level PAP (with or
without backup rate) therapy, regardless of the underlying medical condition,
shall not be paid in the FSS payment category. A ventilator is not eligible
for reimbursement for any of the conditions described in this RAD LCD even
though the ventilator equipment may have the capability of operating in a bi-
level PAP (E0470, E0471) mode. Claims for ventilators used to provide CPAP or
bi-level CPAP therapy for conditions described in this RAD policy will be
denied as not reasonable and necessary.

General principles of correct coding require that products assigned to a
specific HCPCS code only be billed using the assigned code. Thus, using the
HCPCS codes for CPAP (E0601) or bi-level PAP (E0470, E0471) devices for a
ventilator (E0465, E0466, or E0467) used to provide CPAP or bi-level PAP
therapy is incorrect coding. Claims for ventilators billed using the CPAP or
bi-level PAP device HCPCS codes will be denied as incorrect coding.

CONTINUED COVERAGE CRITERIA FOR E0470 AND E0471 DEVICES BEYOND THE FIRST THREE
MONTHS OF THERAPY

Beneficiaries covered for the first three months of an E0470 or an E0471
device must be re-evaluated to establish the medical necessity of continued
coverage by Medicare beyond the first three months. While the beneficiary may
certainly need to be evaluated at earlier intervals after this therapy is
initiated, the re-evaluation upon which Medicare will base a decision to
continue coverage beyond this time must occur no sooner than 61 days after
initiating therapy by the treating practitioner. Medicare will not continue
coverage for the fourth and succeeding months of therapy until this re-
evaluation has been completed.

There must be documentation in the beneficiary's medical record about the
progress of relevant symptoms and beneficiary usage of the device up to that
time. Failure of the beneficiary to be consistently using the E0470 or E0471
device for an average of 4 hours per 24 hour period by the time of the re-
evaluation (on or after 61 days after initiation of therapy) would represent
non-compliant utilization for the intended purposes and expectations of
benefit of this therapy. This would constitute reason for Medicare to deny
continued coverage as not reasonable and necessary.

A signed and dated statement completed by the treating practitioner no sooner
than 61 days after initiating use of the device, declaring that the
beneficiary is compliantly using the device (an average of 4 hours per 24 hour
period) and that the beneficiary is benefiting from its use must be obtained
by the supplier of the device for continued coverage beyond three months.

If the above criteria are not met, continued coverage of an E0470 or an E0471
device and related accessories will be denied as not reasonable and necessary.

ACCESSORIES

The following table represents the usual maximum amount of accessories
expected to be reasonable and necessary:

A4604 | 1 per 3 months  
---|---  
A7027 | 1 per 3 months  
A7028 | 2 per 1 month  
A7029 | 2 per 1 month  
A7030  | 1 per 3 months  
A7031  | 1 per 1 month  
A7032 | 2 per 1 month  
A7033 | 2 per 1 month  
A7034 | 1 per 3 months  
A7035 | 1 per 6 months  
A7036  | 1 per 6 months  
A7037  | 1 per 3 months  
A7038 | 2 per 1 month  
A7039 | 1 per 6 months  
A7046  | 1 per 6 months  
  
  
Billing for quantities of supplies greater than those described in the policy
as the usual maximum amounts, will be denied as not reasonable and necessary.

Either a non-heated (E0561) or heated (E0562) humidifier is covered and paid
separately when ordered by the treating practitioner for use with a covered
E0470 or E0471 RAD.

GENERAL

A Standard Written Order (SWO) must be communicated to the supplier before a
claim is submitted. If the supplier bills for an item addressed in this policy
without first receiving a completed SWO, the claim shall be denied as not
reasonable and necessary.

For Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS)
base items that require a Written Order Prior to Delivery (WOPD), the supplier
must have received a signed SWO before the DMEPOS item is delivered to a
beneficiary. If a supplier delivers a DMEPOS item without first receiving a
WOPD, the claim shall be denied as not reasonable and necessary. Refer to the
LCD-related Policy Article, located at the bottom of this policy under the
Related Local Coverage Documents section.

For DMEPOS base items that require a WOPD, and also require separately billed
associated options, accessories, and/or supplies, the supplier must have
received a WOPD which lists the base item and which may list all the
associated options, accessories, and/or supplies that are separately billed
prior to the delivery of the items. In this scenario, if the supplier
separately bills for associated options, accessories, and/or supplies without
first receiving a completed and signed WOPD of the base item prior to
delivery, the claim(s) shall be denied as not reasonable and necessary.

An item/service is correctly coded when it meets all the coding guidelines
listed in CMS HCPCS guidelines, LCDs, LCD-related Policy Articles, or DME MAC
articles. Claims that do not meet coding guidelines shall be denied as not
reasonable and necessary/incorrectly coded.

Proof of delivery (POD) is a Supplier Standard and DMEPOS suppliers are
required to maintain POD documentation in their files. Proof of delivery
documentation must be made available to the Medicare contractor upon request.
All services that do not have appropriate proof of delivery from the supplier
shall be denied as not reasonable and necessary.

REFILL REQUIREMENTS

For DMEPOS items and supplies provided on a recurring basis, billing must be
based on prospective, not retrospective use. For DMEPOS products that are
supplied as refills to the original order, suppliers must contact the
beneficiary, and document an affirmative response, prior to dispensing the
refill and not automatically ship on a pre-determined basis, even if
authorized by the beneficiary. This shall be done to ensure that the refilled
item remains reasonable and necessary, existing supplies are expected to end,
and to confirm any changes or modifications to the order. Contact with the
beneficiary or designee regarding refills must take place no sooner than 30
calendar days prior to the expected end of the current supply. For delivery of
refills, the supplier must deliver the DMEPOS product no sooner than 10
calendar days prior to the expected end of the current supply. This is
regardless of which delivery method is utilized.

For all DMEPOS items that are provided on a recurring basis, suppliers are
required to have contact with the beneficiary or caregiver/designee and
document an affirmative response, prior to dispensing a new supply of items.
Suppliers must not deliver refills without a refill request and an affirmative
response from a beneficiary. Items delivered without a valid, documented
refill request will be denied as not reasonable and necessary.

Suppliers must not dispense a quantity of supplies exceeding a beneficiary's
expected utilization. Suppliers must stay attuned to changed or atypical
utilization patterns on the part of their clients. Suppliers must verify with
the treating practitioners that any changed or atypical utilization is
warranted. Regardless of utilization, a supplier must not dispense more than a
three (3) - month quantity at a time.

REPLACEMENT

This section applies to E0470 and E0471 devices initially provided for the
scenarios addressed in this policy and reimbursed while the beneficiary was in
Medicare fee-for-service (FFS).

If an E0470 or E0471 device is replaced during the 5 year reasonable useful
lifetime (RUL) because of loss, theft, or irreparable damage due to a specific
incident, there is no requirement for a new clinical evaluation or testing.

If an E0470 or E0471 device is replaced following the 5 year RUL, there must
be an in-person evaluation by their treating practitioner that documents that
the beneficiary continues to use and benefit from the device. There is no
requirement for new testing. A new prescription is required.

Refer to the repair and replacement information in the Supplier Manual for
additional information.

BENEFICIARIES ENTERING MEDICARE

For beneficiaries who received an E0470 or E0471 device prior to enrollment in
fee-for-service (FFS) Medicare and are seeking Medicare reimbursement for a
rental, either to continue using the existing device or for a replacement
device, coverage transition is not automatic. These claims are considered to
be new, initial rentals for Medicare. Therefore all current coverage and
documentation requirements set out in this policy must be met with the
exceptions noted below.

Qualification Testing - Use of testing performed prior to Medicare eligibility
is allowed. There must be documentation that the beneficiary had the testing
required by the applicable scenario e.g., oximetry, sleep testing, or
spirometry, prior to FFS Medicare enrollment, that meets the current coverage
criteria in effect at the time that the beneficiary seeks Medicare coverage of
a replacement device and/or accessories; and

Clinical Evaluation - Following enrollment in FFS Medicare, the beneficiary
must have an in-person evaluation by their treating practitioner who documents
all of the following in the beneficiary's medical record:

  * The beneficiary has the qualifying medical condition for the applicable scenario; and
  * The testing performed, date of the testing used for qualification and results; and
  * The beneficiary continues to use the device; and
  * The beneficiary is benefiting from the treatment.

SLEEP TESTS

Coverage and payment rules for diagnostic sleep tests may be found in the CMS
National Coverage Determination (NCD) 240.4.1 (CMS Pub. 100-03, Chapter 1,
Part 4), the applicable A/B MAC LCDs and Billing and Coding articles.

Payment for a RAD device for the treatment of the conditions specified in this
policy may be contingent upon an evaluation for the diagnosis sleep apnea
(Obstructive Sleep Apnea, Central Sleep Apnea and/or Complex Sleep Apnea).
Diagnosis of sleep apnea is based upon a sleep test that meets the Medicare
coverage criteria in effect for the date of service of the claim for the RAD
device. The sleep test must be either a polysomnogram performed in a facility-
based laboratory (Type I study) or an inpatient hospital-based or home-based
sleep test (HST) (Types II, III, IV, Other).

Coverage of a RAD device for the treatment of sleep-disordered breathing is
limited to claims where the diagnosis is based on all of the following:

  1. A sleep test (Type I, II, III, IV, Other) that meets the Medicare requirements for a valid sleep test as outlined in NCD 240.4.1 and the applicable A/B MAC LCD and Billing and Coding article; and,
  2. A sleep test that is approved by the Food and Drug Administration (FDA) as a diagnostic device; and,
  3. The sleep test results meet the coverage criteria in effect for the date of service of the claim for the RAD device; and,
  4. The sleep test is ordered by the beneficiary's treating practitioner; and,
  5. The sleep test is conducted by an entity that qualifies as a Medicare provider of sleep tests and is in compliance with all applicable state regulatory requirements.